In Trading, Results Matter.
Our Top 10 exits in last 5 trading days.

Eagle Pharmaceuticals, Inc.. Trade Record

NASDAQ:EGRX Eagle Pharmaceuticals, Inc. stock gains 5.92% Exit Oct 31, 2019 a Trade Record by priceseries

Trade Chart
Trade Chart EGRX Oct 9, 2019, priceSeries
About Eagle Pharmaceuticals, Inc.

Eagle Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers argatroban for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; non-alcohol docetaxel injection, a chemotherapeutic agent for breast, non-small cell lung, prostate, head, and neck cancers/gastric adenocarcinoma; and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates includes include EP-4104, a dantrolene sodium for exertional heat stroke; EGL-4104-C-1702, dantrolene sodium for drug induced hyperthermia; EP-5101 (pemetrexed) for lung cancer and mesothelioma; and EGL-5385-C-1701 (fulvestrant) for breast cancer. Eagle Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Woodcliff Lake, New Jersey.

Trade Information
Trade Type
Entry Date
Oct 9, 2019
Entry Price
Sell Date
Oct 31, 2019
Sell Price
Net Gain
Hold Time
16 Trading Days